{"created":"2023-05-15T09:17:58.831339+00:00","id":1104,"links":{},"metadata":{"_buckets":{"deposit":"1cf3b056-f228-4452-b46e-8d19aec5e29c"},"_deposit":{"created_by":15,"id":"1104","owners":[15],"pid":{"revision_id":0,"type":"depid","value":"1104"},"status":"published"},"_oai":{"id":"oai:iuhw.repo.nii.ac.jp:00001104","sets":["2:148"]},"author_link":["2381","165","2388","2382","165","2389"],"control_number":"1104","item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021-02-20","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"25","bibliographicPageStart":"17","bibliographicVolumeNumber":"26","bibliographic_titles":[{"bibliographic_title":"国際医療福祉大学学会誌","bibliographic_titleLang":"ja"},{"bibliographic_title":"Journal of the International University of Health and Welfare","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"はじめに：ホルモン受容体陽性,HER2 陰性の手術不能又は再発乳がんに対する一次治療としてのパルボシクリブ(PAL)＋レトロゾール(LET)療法の LET 単独療法に対する費用対効果を評価した.\n方法：マルコフモデルを構築し 15 年にわたるシミュレーションをした.公的医療の立場から分析し,直接医療費を算出し評価した.効果指標は質調整生存年(QALY)を用いた.費用対効果は増分費用効果比(ICER)を用いて評価し,費用と QALY は年率 2% で現在価値に割り引いた.結果の頑健性は一元感度分析で評価した. 結果：LET に対する PAL の上乗せによる増分費用は 8,670,801 円であった.増分 QALY は 0.388QALY であった. 単独療法を基準とした場合の併用療法の ICER は 22,345,821 円 /QALY であり,本邦において抗がん剤による費 用対効果が優れるとされる上限値 750 万円 /QALY を上回った.一元感度分析によっても結果の頑健性が示唆された.\n考察：PAL ＋ LET 療法は,LET 単独療法と比較して費用対効果に優れる治療とはいえなかった.","subitem_description_type":"Abstract"}]},"item_10001_description_6":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"Purpose: To evaluate the cost-effectiveness of palbociclib (PAL) plus letrozole (LET) compared with LET alone as first-line therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) unresectable or recurrent breast cancer.\nMethods: We developed a Markov model to estimate the cost-effectiveness of PAL plus LET compared with LET alone over a 15-year period. Cost-effectiveness analysis was performed from the Japanese healthcare payerʼ s perspective. Clinical outcomes were derived from the PALOMA-1 and PALOMA-2 studies. Quality-adjusted life year (QALY) and incremental cost-effectiveness ratio (ICER) were calculated. Direct medical costs and QALY were discounted at 2% per year. One-way sensitivity analyses were performed to estimate the uncertainty of the results.\nResults: Incremental costs and QALY when PAL was added to LET therapy were 8,670,801 JPY and 0.388 QALY, respectively. ICER between PAL plus LET and LET alone was 22,345,821 JPY/QALY. ICER exceeded 7.5 million JPY/ QALY, which was the willingness-to-pay threshold for anti-cancer drugs in Japan. According to one-way sensitivity analyses, PAL plus LET therapy was not cost-effective.\nConclusion: PAL plus LET was not cost-effective compared with LET alone for first-line treatment of advanced breast cancer in Japan.","subitem_description_language":"en","subitem_description_type":"Other"}]},"item_10001_full_name_3":{"attribute_name":"著者別名","attribute_value_mlt":[{"nameIdentifiers":[{}],"names":[{"name":"MORIMOTO, Takashi"}]},{"nameIdentifiers":[{}],"names":[{"name":"IKEDA, SHUNYA"}]},{"nameIdentifiers":[{}],"names":[{"name":"YAMAZAKI, Tsutomu"}]}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"国際医療福祉大学学会","subitem_publisher_language":"ja"}]},"item_10001_radio_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_radio_item":"publisher","subitem_radio_language":"en"}]},"item_10001_source_id_11":{"attribute_name":"書誌レコードID（NCID）","attribute_value_mlt":[{"subitem_source_identifier":"AA12537130","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"21863652","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"MORIMOTO, Takashi","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"IKEDA, SHUNYA","creatorNameLang":"en"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"YAMAZAKI, Tsutomu","creatorNameLang":"en"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-03-02"}],"displaytype":"simple","filename":"26_1(17-25p).pdf","filesize":[{"value":"524.7 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"本文(PDF)","url":"https://iuhw.repo.nii.ac.jp/record/1104/files/26_1(17-25p).pdf"},"version_id":"55647484-ed52-42b8-965c-f5cd98c53183"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"パルボシクリブ","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"レトロゾール","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"費用効用分析","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"手術不能又は再発乳がん","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"palbociclib","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"letrozole","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Cost-effectiveness","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"advanced breast cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Cost-effectiveness analysis of palbociclib as first-line treatment for patients with ER-positive, HER2-negative advanced breast cancer in Japan","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Cost-effectiveness analysis of palbociclib as first-line treatment for patients with ER-positive, HER2-negative advanced breast cancer in Japan","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"15","path":["148"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-03-02"},"publish_date":"2021-03-02","publish_status":"0","recid":"1104","relation_version_is_last":true,"title":["Cost-effectiveness analysis of palbociclib as first-line treatment for patients with ER-positive, HER2-negative advanced breast cancer in Japan"],"weko_creator_id":"15","weko_shared_id":-1},"updated":"2023-07-10T06:21:57.280813+00:00"}